Medicus Pharma LTD Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Medicus Pharma Ltd. Chief Operating Officer Andrew Alasdair Smith was granted 200,000 stock options exercisable at $0.36 per share.
NASDAQ
Director Cathy McMorris Rodgers was granted 50,000 stock options in Medicus Pharma Ltd. on June 3, 2026.
NASDAQ
Director Ajay Raju acquired 50,000 stock options in Medicus Pharma Ltd. (MDCX) with an exercise price of $0.36, vesting over one year.
NASDAQ
Faisal Mehmud, Chief Medical Officer of Medicus Pharma Ltd., was granted stock options for 250,000 shares.
NASDAQ
Medicus Pharma Director Sara R. May acquired 50,000 stock options with an exercise price of $0.36, vesting over one year.
NASDAQ
Medicus Pharma Ltd. director Patrick J. Mahaffy acquired 50,000 stock options with an exercise price of $0.36, vesting over one year.
NASDAQ
Medicus Pharma Director Larry Kaiser acquired 50,000 stock options with an exercise price of $0.36, vesting over one year.
NASDAQ
Director Barry Fishman of Medicus Pharma Ltd. acquired 50,000 stock options with an exercise price of $0.36, vesting over one year.
NASDAQ
Robert J. Ciaruffoli, a Director at Medicus Pharma Ltd., acquired 50,000 stock options through a grant on June 3, 2026, with a vesting schedule over one year.
NASDAQ
Edward J. Brennan, Chief Scientific Officer of Medicus Pharma Ltd., reported the acquisition of stock options.
NASDAQ
Carolyn F. Bonner, President and CFO of Medicus Pharma Ltd., was granted a stock option for 250,000 common shares.
NASDAQ
Raza Bokhari, CEO and Director of Medicus Pharma Ltd., acquired 500,000 stock options with an exercise price of $0.36, vesting over one year.
NASDAQ
William Ashton, a Director at Medicus Pharma Ltd., acquired 50,000 stock options with an exercise price of $0.36.
NASDAQ
Medicus Pharma Ltd.'s Chief Operating Officer, Andrew A. Smith, acquired 50,000 stock options with an exercise price of $0.50.
NASDAQ
Medicus Pharma Ltd. Director Cathy McMorris Rodgers was granted 25,000 stock options with an exercise price of $0.50.
NASDAQ
Medicus Pharma Ltd. Director Ajay Raju acquired 25,000 stock options with an exercise price of $0.5, exercisable from March 26, 2027.
NASDAQ
Medicus Pharma's Chief Medical Officer, Faisal Mehmud, acquired 125,000 stock options with an exercise price of $0.50, exercisable from March 26, 2027.
NASDAQ
Medicus Pharma Ltd. Director Sara R. May acquired 25,000 stock options with an exercise price of $0.5, exercisable from March 26, 2027.
NASDAQ
Medicus Pharma Director Patrick J. Mahaffy reported the acquisition of 25,000 stock options with an exercise price of $0.50.
NASDAQ
Medicus Pharma Ltd. director and 10% owner Larry Kaiser acquired 25,000 stock options with an exercise price of $0.5.
NASDAQ
Medicus Pharma Ltd. Director and 10% owner Barry Fishman acquired 25,000 stock options with an exercise price of $0.50.
NASDAQ
Medicus Pharma Ltd. Director Robert J. Ciaruffoli acquired 25,000 stock options with an exercise price of $0.5, exercisable from March 26, 2027.
NASDAQ
Medicus Pharma's Chief Scientific Officer, Edward J. Brennan, acquired 25,000 stock options with an exercise price of $0.5 per share.
NASDAQ
Medicus Pharma's President and CFO, Carolyn F. Bonner, was granted 100,000 stock options with an exercise price of $0.50, signaling potential long-term alignment.
NASDAQ
Medicus Pharma Ltd.'s CEO, Raza Bokhari, acquired 325,000 stock options at an exercise price of $0.50, exercisable from March 26, 2027.
NASDAQ
Medicus Pharma Ltd. Director and 10% owner William Ashton acquired 25,000 stock options with an exercise price of $0.50.
NASDAQ
Medicus Pharma Ltd.'s Chief Operating Officer, Andrew Alasdair Smith, was granted 50,000 stock options with an exercise price of $1.8.
NASDAQ
Medicus Pharma Ltd. director Cathy McMorris Rodgers was granted 25,000 stock options with an exercise price of $1.80, vesting quarterly over one year.
NASDAQ
Medicus Pharma Ltd. Director Ajay Raju was granted 25,000 stock options with an exercise price of $1.80, vesting quarterly over one year.
NASDAQ
Medicus Pharma's Chief Medical Officer, Faisal Mehmud, was granted 75,000 stock options with an exercise price of $1.8, vesting quarterly over one year.